Results 261 to 270 of about 178,517 (322)

Computational Investigation of the Covalent Inhibition Mechanism of Bruton's Tyrosine Kinase by Ibrutinib. [PDF]

J Chem Inf Model
Barragan AM, Ghaby K, Pond MP, Roux B.
europepmc   +1 more source

E41K mutation activates Bruton's tyrosine kinase by stabilizing an inositol hexakisphosphate-dependent invisible dimer. [PDF]

J Biol Chem
Chowdhury S, Chakraborty MP, Roy S, Dey BP, Gangopadhyay K, Das R.   +5 more
europepmc   +1 more source

Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma: New hopes on the horizon. [PDF]

World J Clin Oncol
Lino-Silva LS, Martínez-Villavicencio SB, Rivera-Moncada LF.   +2 more
europepmc   +1 more source

The contribution of Bruton's tyrosine kinase to innate host defense during bacterial infections [PDF]

Liu, Z.
core   +2 more sources

Screening and Characterization of Allosteric Small Molecules Targeting Bruton's Tyrosine Kinase. [PDF]

Biochemistry
Kueffer LE, Lin DY, Amatya N, Serrenho J, Joseph RE, Courtney AH, Andreotti AH.   +6 more
europepmc   +1 more source

Evidence-based expert consensus on clinical management of safety of Bruton's tyrosine kinase inhibitors (2024). [PDF]

Chin J Cancer Res
Song Z, Jiang D, Yu L, Chen Y, Zhou D, Li Y, Wu D, Zhang L, Miao L, Ma J, Zhu J, Jing H, Zhao R, Steering Committee OBOT, Evidence-Based Pharmacy Professional Committee Of Chinese Pharmaceutical Association Cpa TCPATESG, Chinese Pharmaceutical Association Cpa HPPCO, Chinese Pharmacological Society Cps DOTDMO, Clinical Oncology Csco ECOLOCSO, Chinese Society Of Clinical Oncology Csco ECOLO, China Anti-Cancer Association Caca SOICO, Chinese Medical Association Cma CSOHO, Cross-Straits Medicine Exchange Association Smea HPPCO.   +21 more
europepmc   +1 more source

The impact of Bruton's tyrosine kinase inhibitor treatment on COVID-19 outcomes in Chinese patients with chronic lymphocytic leukemia. [PDF]

Front Oncol
Yang S, Wei R, Shi H, Wang Y, Lai Y, Zhao X, Lu J, Schmitz N.   +7 more
europepmc   +1 more source

Bruton's tyrosine kinase (Btk) のSH3ドメイン結合蛋白質SabによるBtk活性の制御 [PDF]

ヤマドリ, トモキ, 山鳥, 大材
core  

Labeling of Bruton's Tyrosine Kinase (BTK) Inhibitor [¹¹C]BIO-2008846 in Three Different Positions and Measurement in NHP Using PET. [PDF]

Int J Mol Sci
Nag S, Datta P, Morén AF, Khani Y, Martarello L, Kaliszczak M, Halldin C.   +6 more
europepmc   +1 more source

Dermatological Toxicities of Bruton’s Tyrosine Kinase Inhibitors

American Journal of Clinical Dermatology, 2020
The development of Bruton's tyrosine kinase (BTK) inhibitors represents a major breakthrough in the treatment of chronic lymphocytic leukemia and other B cell malignancies. The first-generation inhibitor ibrutinib works by covalent irreversible binding to BTK, a non-receptor tyrosine kinase of the TEC (transient erythroblastopenia of childhood) family ...
V. Sibaud, M. Beylot‐Barry, C. Protin, E. Vigarios, C. Récher, L. Ysebaert   +5 more
semanticscholar   +4 more sources